Questions: Schizophrenia: Positive and Negative Symptoms

Question 1

A patient on a first-generation antipsychotic shows significantly reduced hallucinations and delusions but develops worsened avolition and flat affect. What best explains this pattern?

• A. The medication unmasked pre-existing negative symptoms that were hidden beneath the positive ones
• B. First-generation antipsychotics block D2 receptors in the mesocortical pathway, reducing prefrontal dopamine signaling and worsening negative symptoms
• C. The dosage is too low — negative symptoms require more aggressive D2 blockade than positive symptoms do
• D. Negative symptoms are an unrelated side effect caused by the drug's sedative properties

Answer: (B)

First-generation antipsychotics are potent D2 blockers — they reduce excess mesolimbic dopamine activity, which controls positive symptoms. But negative symptoms are associated with *insufficient* dopamine in the mesocortical pathway (to the prefrontal cortex). Blocking D2 receptors there worsens an already deficient signal, exacerbating negative symptoms. This is why first-gen antipsychotics often control positive symptoms while making avolition, flat affect, and alogia worse.

Question 2

A clinician says: 'Positive symptoms of schizophrenia are the ones that benefit the patient, while negative symptoms are the harmful ones.' What is wrong with this claim?

• A. Nothing — positive symptoms like hallucinations can sometimes be experienced as pleasurable
• B. The positive/negative distinction refers to excess versus deficit of normal function, not beneficial versus harmful effects — both categories are harmful
• C. The terms should be reversed: negative symptoms are the ones that add to normal functioning
• D. The distinction is outdated; modern psychiatry uses only the term 'psychotic features'

Answer: (B)

The positive/negative terminology comes from neurology, not everyday usage. 'Positive' means something is added or in excess relative to normal function (hallucinations, delusions, disorganized behavior). 'Negative' means something is reduced or absent (alogia, avolition, anhedonia, flat affect). Both categories represent serious impairments. The misconception — that 'positive' means good — is extremely common and leads to confusion about why patients on antipsychotics may still suffer profoundly.

Question 3

Negative symptoms of schizophrenia generally respond better to antipsychotic medications than positive symptoms do.

• T. True
• F. False

Answer: False

The opposite is true. Positive symptoms arise from excess mesolimbic dopamine activity, so D2-blocking antipsychotics directly target their mechanism. Negative symptoms are associated with mesocortical dopamine *deficiency*, and first-generation antipsychotics can actually worsen them by further reducing prefrontal dopamine. Second-generation atypicals show modest improvement in negative symptoms, but negative symptoms remain more treatment-resistant overall — and are also the stronger predictors of long-term functional impairment.

Question 4

Cognitive deficits in schizophrenia — such as impairments in working memory, processing speed, and attention — typically precede the onset of frank psychosis and persist even when positive symptoms are well controlled.

• T. True
• F. False

Answer: True

Cognitive deficits are now understood as a core, semi-independent symptom dimension of schizophrenia. They appear before the first psychotic episode (often in adolescence), persist during periods of remission when hallucinations and delusions are controlled, and are the strongest predictors of functional recovery — more so than positive symptom control. This is why treatment increasingly includes cognitive remediation and psychosocial rehabilitation, not only pharmacology.

Question 5

Why do first-generation antipsychotics that successfully reduce hallucinations and delusions often fail to improve — and may worsen — the negative symptoms of schizophrenia?

Model answer: Because positive and negative symptoms have opposite dopamine problems in different pathways. Positive symptoms arise from excess dopamine in the mesolimbic pathway; D2 blockers reduce this and control positive symptoms. Negative symptoms are associated with insufficient dopamine in the mesocortical pathway to the prefrontal cortex. Blocking D2 receptors there worsens an already deficient signal, exacerbating avolition, flat affect, and alogia.

This distinction — mesolimbic hyperdopaminergia driving positive symptoms vs. mesocortical hypodopaminergia driving negative symptoms — is the central neurobiological framework of the positive/negative distinction. It explains why the same drug class that treats one symptom cluster can worsen the other, why second-generation antipsychotics (with broader receptor profiles and weaker D2 blockade) offer modest advantages for negative symptoms, and why clozapine — which acts on serotonin, histamine, and muscarinic receptors as well as D2 — remains most effective for treatment-resistant cases.